Regier, Dean A. http://orcid.org/0000-0001-8876-0511
Pollard, Samantha http://orcid.org/0000-0002-3070-2092
McPhail, Melanie http://orcid.org/0000-0001-7156-5162
Bubela, Tania
Hanna, Timothy P. http://orcid.org/0000-0003-3228-6042
Ho, Cheryl
Lim, Howard J.
Chan, Kelvin
Peacock, Stuart J.
Weymann, Deirdre
Funding for this research was provided by:
This research was supported by Genome British Columbia/Genome Canada (G05CHS) and the Terry Fox Research Institute.
Article History
Received: 11 March 2022
Accepted: 29 September 2022
First Online: 25 October 2022
Competing interests
: The authors declare no competing non-financial interests but the following competing financial interests: D.A.R. has received honoraria from Roche Canada and AstraZeneca; his institution has received research funding for a project from Roche Canada. D.W. and S.P. co-direct IMPRINT Research Consulting and have consulted for Roche Canada and AstraZeneca Canada. H.J.L. has received honoraria from Eisai, Taiho, Roche, Lilly, BMS, Amgen, and Leo for consultant work and is an investigator on trials with Bayer, BMS, Lilly, Roche, Astra-Zeneca, and Amgen. Cheryl Ho reports consultancy work through advisory boards with Abbvie, Amgen, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Merck, Novartis, Pfizer, Roche, and Takeda and has research grants from AstraZeneca, EMD Serono, and Roche.